

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

GI 6707PCT-US

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/485951

INTERNATIONAL APPLICATION NO.
PCT/JP98/03670INTERNATIONAL FILING DATE
19 August 1998 (19.08.98)PRIORITY DATE CLAIMED
22 August 1997 (22.08.97)

TITLE OF INVENTION

HUMAN GALECTIN-9-LIKE PROTEINS AND CDNAS ENCODING THESE PROTEINS

APPLICANT(S) FOR DO/EO/US

Seishi KATO, Tomoko YAMAGUCHI, Shingo SEKINE, Kouju KAMATA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☐ Other items or information:

"Express Mail" mailing label number. EE32046274W
Date of Deposit: February 17, 2000
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner For Patents, Washington, D.C. 20231

[Signature]

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/485951)	INTERNATIONAL APPLICATION NO. PCT/JP98/03670	ATTORNEY'S DOCKET NUMBER GI 6707PCT-US
--	---	---

20. The following fees are submitted..

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- | | |
|--|------------|
| <input type="checkbox"/> Search Report has been prepared by the EPO or JPO | \$930.00 |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) | \$720.00 |
| <input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) | \$790.00 |
| <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO | \$1,070.00 |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) | \$98.00 |

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$1,070.00**
 Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).
\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	- 20 =	0	x \$22.00
Independent claims	- 3 =	0	x \$82.00

\$0.00**\$0.00**Multiple Dependent Claims (check if applicable). ☐**\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$1,070.00**Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐**\$0.00****SUBTOTAL =****\$1,070.00**Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

+

\$0.00**TOTAL NATIONAL FEE =****\$1,070.00**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐**\$40.00****TOTAL FEES ENCLOSED =****\$1,110.00**Amount to be:
refunded

\$

charged

\$

- ☐ A check in the amount of _____ to cover the above fees is enclosed.
- ☒ Please charge my Deposit Account No. **07-1060** in the amount of **\$1,110.00** to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **07-1060** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

 Suzanne A. Sprunger, Ph.D., Esq.
 AMERICAN HOME PRODUCTS CORPORATION
 Patent & Trademark Department - 2B
 One Campus Drive
 Parsippany, New Jersey 07054

SIGNATURE

Suzanne A. Sprunger, Ph.D., Esq.

NAME

41,323

REGISTRATION NUMBER

February 17, 2000

DATE

4/PRTS

WO 99/10490

"Express Mail" mailing label number: EE632046274W
 Date of Deposit: February 17, 2000
 I hereby certify that this paper or fee is being
 deposited with the United States Postal Service
 "Express Mail Post Office to Addressee" service
 under 37 CFR 1.10 or the date indicated above
 and is addressed to the Assistant Commissioner
 For Patents, Washington, D.C. 20231

DESCRIPTION

416 Rec'd PCT/PTO 17 FEB 2000

HUMAN GALECTIN-9-LIKE PROTEINS AND CDNAS ENCODING THESE PROTEINS

5

FIELD OF THE INVENTION

The present invention relates to galactin-9-like proteins and cDNAs coding for these proteins. The proteins of the present invention can be employed as pharmaceuticals or reagents for sugar chain researches. The human cDNAs of the present invention can be utilized as probes for the gene diagnosis and gene sources for the gene therapy. Furthermore, the cDNAs can be utilized as gene sources for large-scale production of the proteins encoded by said cDNAs.

15

BACKGROUND OF THE INVENTION

Galectins are the general term for animal lectins binding to galactose. Animal lectins exist in many sites such as the cytoplasm, the nucleus, the cell membrane surface, etc., and are considered to be associated with the cell proliferation, the differentiation, the canceration, the metastasis, the immunity, and so on [Dickamer, K., Annu. Rev. Cell Biol. 9: 237-264 (1993)]. There have been heretofore known 9 kinds of galectins, namely galectin-1 to galectin-9.

25

Galectin-9 is a lectin that has been identified as an antigenic protein reacting with an antibody contained in the serum of patients with Hodgkin's disease [Tureci, O., J. Biol. Chem.

272: 6416-6422 (1997)]. Galectin-9 has a structure where two sugar chain-binding domains are connected by a linker peptide, in the same manner as in galectin-4 and galectin-8. The true role of galectin-9 in the living body has not yet been completely clarified, but it has been considered to be involved in the adhesion between cells. Although two types of galectin-9 having different molecular weights in mice have been reported [Wada, J. and Kanwar, Y. S., J. Biol. Chem. 272: 6078-6086 (1997)], there have not been reported such isoforms in the human.

SUMMARY OF THE INVENTION

The object of the present invention is to provide human galectin-9-like proteins and cDNAs encoding these proteins.

As the result of intensive studies, the present inventors have been successful in cloning of human cDNAs coding for galectin-9-like proteins, thereby completing the present invention. In other words, the present invention provides galectin-9-like proteins, namely proteins containing the amino acid sequences represented by Sequence No. 1 and Sequence No. 2.

Moreover, the present invention provides cDNAs coding for the above-mentioned proteins and containing the base sequences represented by Sequence No. 3 to Sequence No. 5.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1: A figure depicting the structure of plasmid pHP01461.

Figure 2: A figure illustrating the results of analysis by SDS-PAGE of (1) a human galectin-9-like protein that is translated

in vitro and (2) a human galectin-9-like protein that is bound to the lactose column.

Figure 3: A figure illustrating the result of northern blot hybridization that was carried out by using the cDNA fragment as a probe.

Figure 4: A figure illustrating the result of northern blot hybridization that was carried out by using the oligonucleotide in the inserted portion as a probe.

10 BEST MODE FOR CARRYING OUT THE INVENTION

The proteins of the present invention can be obtained, for example, by a method for isolation from human organs, cell lines, etc., a method for preparation of peptides by the chemical synthesis, or a method for production with the recombinant DNA technology using the DNAs coding for the human galactin-9-like proteins of the present invention, wherein the method for obtainment by the recombinant DNA technology is employed preferably. For instance, in vitro expression can be achieved by preparation of an RNA by in vitro transcription from a vector having one of cDNAs of the present invention, followed by in vitro translation using this RNA as a template. Also, recombination of the translation region into a suitable expression vector by the method known in the art leads to expression of a large amount of the encoded protein by using *Escherichia coli*, *Bacillus subtilis*, yeasts, animal cells, and so on.

In the case in which a protein of the present invention is expressed by a microorganism such as *Escherichia coli*, a

recombinant expression vector bearing the translation region in the cDNA of the present invention is constructed in an expression vector having an origin, a promoter, a ribosome-binding site, a cDNA-cloning site, a terminator etc., which can be replicated in the microorganism, and, after transformation of the host cells with said expression vector, the thus-obtained transformant is incubated, whereby the protein encoded by said cDNA can be produced on a large scale in the microorganism. Alternatively, a fusion protein with another protein can be expressed. Only a protein portion coding for said cDNA can be obtained by cleavage of said fusion protein with an appropriate protease. Said fusion protein, provided that it possesses the lactose-binding activity, shall come within the scope of the present invention.

In the case in which a protein of the present invention is subjected to secretory expression in animal cells, the protein of the present invention can be produced by extracellular secretion, when the translation region of said cDNA is subjected to recombination to an expression vector for animal cells that has a promoter, a splicing region, a poly(A) addition site, etc., followed by introduction into the animal cells.

The proteins of the present invention include peptide fragments (more than 5 amino acid residues) containing any partial amino acid sequence in the amino acid sequence represented by Sequence No. 1. These peptide fragments can be utilized as antigens for preparation of antibodies. Hereupon, the proteins of the present invention are secreted in an extracellular manner. Since a portion capable of binding sugar chains exists in the amino acid

sequence, proteins where sugar chains are added can be obtained by expression in appropriate animal cells. Accordingly, such proteins or peptides wherein sugar chains are added shall come within the scope of the present invention.

5 The DNAs of the present invention include all DNAs coding for the above-mentioned proteins. Said DNAs can be obtained by using a method by chemical synthesis, a method by cDNA cloning, and so on.

 The human cDNAs of the present invention can be cloned from
10 cDNA libraries of the human cell origin. These cDNA libraries are constructed by using as templates poly(A)⁺ RNAs extracted from human cells. The human cells may be cells delivered from the human body, for example, by the operation or may be the culture cells. A poly(A)⁺ RNA isolated from a stomach cancer tissue is used in
15 Examples. The cDNAs can be synthesized by using any method selected from the Okayama-Berg method [Okayama, H. and Berg, P., Mol. Cell. Biol. 2: 161-170 (1982)], the Gubler-Hoffman method [Gubler, U. and Hoffman, J. Gene 25: 263-269 (1983)], and so on, but it is preferred to use the capping method [Kato, S. et al., Gene 150:
20 243-250 (1994)] in order to obtain a full-length clone in an effective manner. The identification of the cDNAs is carried out by the determination of the whole base sequence by the sequencing, the search of known proteins having sequences analogous to the amino acid sequence predicted from the base sequence, expression
25 of proteins by in vitro translation, expression by *Escherichia coli*, and the activity measurement of expressed products. The activity measurement is carried out by identification of the

binding with lactose.

The cDNAs of the present invention are characterized by containing the base sequence represented by Sequence No. 3 or Sequence No. 4. For example, that represented by Sequence No. 5 possesses a 1725-bp base sequence with a 1068-bp open reading frame. This open reading frame codes for a protein consisting of 355 amino acid residues. This protein possesses such a high 69.3% analogy to the mouse galectin-9-like isoform in the amino acid sequence level.

Hereupon, the same clones as the cDNAs of the present invention can be easily obtained by screening of the human cDNA libraries constructed from the human cells by the use of an oligonucleotide probe synthesized on the basis of the cDNA base sequence described in Sequence No. 3.

In general, the polymorphism due to the individual difference is frequently observed in human genes. Accordingly, any cDNA that is subjected to insertion or deletion of one or plural nucleotides and/or substitution with other nucleotides in Sequence No. 3 to Sequence No. 5 shall come within the scope of the present invention.

In a similar manner, any protein that is formed by these modifications comprising insertion or deletion of one or plural amino acids and/or substitution with other amino acids shall come within the scope of the present invention, as far as the protein possesses the human galectin-9-like activity.

The cDNAs of the present invention include cDNA fragments (more than 10 bp) containing any partial base sequence in the base

sequence represented by Sequence No. 3. Also, DNA fragments consisting of a sense chain and an anti-sense chain shall come within this scope. These DNA fragments can be utilized as the probes for the gene diagnosis.

- 5 The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the
- 10 genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in
- 15 accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An
- 20 "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

- Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences
- 25 disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA

transcribed from the gene (Albert and Morris, 1994, Trends Pharmacol. Sci. 15(7): 250-254; Lavarosky et al., 1997, Biochem. Mol. Med. 62(1): 11-22; and Hampel, 1998, Prog. Nucleic Acid Res. Mol. Biol. 58: 1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, Bioessays 14(9): 629-633; Zwaal et al., 1993, Proc. Natl. Acad. Sci. USA 90(16): 7431-7435; Clark et al., 1994, Proc. Natl. Acad. Sci. USA 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al., 1988, Nature 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992;

5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein

fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide, as determined by those of skill in the art. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous, or related to that encoded by the polynucleotides.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below:

highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Table 1

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) [‡]	Hybridization Temperature and Buffer [†]	Wash Temperature and Buffer [†]
A	DNA : DNA	≥50	65°C; 1×SSC -or- 42°C; 1×SSC, 50% formamide	65°C; 0.3×SSC
B	DNA : DNA	<50	T _B *; 1×SSC	T _B *; 1×SSC
C	DNA : RNA	≥50	67°C; 1×SSC -or- 45°C; 1×SSC, 50% formamide	67°C; 0.3×SSC
D	DNA : RNA	<50	T _D *; 1×SSC	T _D *; 1×SSC
E	RNA : RNA	≥50	70°C; 1×SSC -or- 50°C; 1×SSC, 50% formamide	70°C; 0.3×SSC
F	RNA : RNA	<50	T _F *; 1×SSC	T _F *; 1×SSC
G	DNA : DNA	≥50	65°C; 4×SSC -or- 42°C; 4×SSC, 50% formamide	65°C; 1×SSC
H	DNA : DNA	<50	T _H *; 4×SSC	T _H *; 4×SSC
I	DNA : RNA	≥50	67°C; 4×SSC -or- 45°C; 4×SSC, 50% formamide	67°C; 1×SSC
J	DNA : RNA	<50	T _J *; 4×SSC	T _J *; 4×SSC
K	RNA : RNA	≥50	70°C; 4×SSC -or- 50°C; 4×SSC, 50% formamide	67°C; 1×SSC
L	RNA : RNA	<50	T _L *; 2×SSC	T _L *; 2×SSC
M	DNA : DNA	≥50	50°C; 4×SSC -or- 40°C; 6×SSC, 50% formamide	50°C; 2×SSC
N	DNA : DNA	<50	T _N *; 6×SSC	T _N *; 6×SSC
O	DNA : RNA	≥50	55°C; 4×SSC -or- 42°C; 6×SSC, 50% formamide	55°C; 2×SSC
P	DNA : RNA	<50	T _P *; 6×SSC	T _P *; 6×SSC
Q	RNA : RNA	≥50	60°C; 4×SSC -or- 45°C; 6×SSC, 50% formamide	60°C; 2×SSC
R	RNA : RNA	<50	T _R *; 4×SSC	T _R *; 4×SSC

‡ : The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by

aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

† : SSPE (1×SSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH7.4) can be substituted for SSC (1×SSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

- 5 *T_B - T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C)=2(#of A + T bases) + 4(# of G + C bases). For hybrids between 10 18 and 49 base pairs in length, T_m(°C)=81.5 + 16.6(log₁₀[Na⁺]) + 0.41 (%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1×SSC=0.165M).

- Additional examples of stringency conditions for
- 15 polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc.,
- 20 sections 2.10 and 6.3-6.4, incorporated herein by reference.

- Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least
- 25 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize
- 30 overlap and identity while minimizing sequence gaps.

EXAMPLES

The present invention is embodied in more detail by the following examples, but this embodiment is not intended to restrict the present invention. The basic operations and the enzyme reactions with regard to the DNA recombination are carried out according to the literature ["Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Laboratory, 1989]. Unless otherwise stated, restrictive enzymes and a variety of modification enzymes to be used were those available from TAKARA SHUZO. The manufacturer's instructions were used for the buffer compositions as well as for the reaction conditions, in each of the enzyme reactions.

(1) cDNA Cloning

Clone HP01461 was obtained as the result of a large-scale sequencing of cDNA clones selected from the cDNA library of human stomach cancer cells (described in WO97/03190). The present clone has a structure consisting of an 81-bp 5'-nontranslation region, a 1068-bp open reading frame, a 576-bp 3'-nontranslation region, and an 83-bp poly(A) tail (Sequence No. 5). The open reading frame codes for a protein consisting of 355 amino acid residues and the search of the protein data base using this sequence has revealed the presence of a high analogy to the amino acid sequences of human galectin-9 and mouse galectin-9 isoform. Table 2 shows the comparison of the amino acid sequence between the human galectin-like protein (HS) of the present invention and the human galectin-9 (G9), while Table 3 shows the comparison of the amino acid sequence between the human galectin-like protein (HS) of the present invention and the mouse galectin-9 isoform (MM). Therein,

the marks of -, *, and . represent a gap, an amino acid residue identical with the protein of the present invention, and an amino acid residue analogous to the protein of the present invention, respectively. Comparison of the protein of the present invention with human galectin-9 has revealed that there are differences at the following 6 sites. That is to say, they are lysine at position 88 (arginine in G), insertion of glycine at position 96, serine at position 135 (phenylalanine in G9), insertion of 32 amino acid residues from position 149 to position 180, proline at position 270 (leucine in G9), and glutamic acid at position 313 (glycine in G9). Because comparison of the protein of the present invention with the mouse galectin-9 isoform has revealed that the protein of the present invention has a sequence that is longer only by 2 amino acid residues and a 69.3% analogy is shown in the entire region, the protein of the present invention is considered to be a homologue of the mouse galectin-9 isoform.

Table 2

20	HS MAFSGSQAPYLSPAVPFSGTIQGGLQDGLQITVNGTVLSSSGTRFAVNFQTGFSGNDIAF *****
	G9 MAFSGSQAPYLSPAVPFSGTIQGGLQDGLQITVNGTVLSSSGTRFAVNFQTGFSGNDIAF
	HS HFNPRFEDGGYVVCNTRQNGSWGPEERKTHMPFQKMPFDLCFLVQSSDFKVMVNGILFV *****.*****
25	G9 HFNPRFEDGGYVVCNTRQNGSWGPEERRTHMPFQK-MPFDLCFLVQSSDFKVMVNGILFV HS QYFHRVPFHRVDTISVNGSVQLSYISFQNPRTVPVQPAFSTVPFSQPVCFPPRPRGRRQK *****
	G9 QYFHRVPFHRVDTIFVNGSVQLSYISFQ-----
	HS PPGVWPANPAPITQTVIHTVQSAPGQMFPSTPAIPPMYPHPAYPMPFITILGGLYPSKS *****
30	

G9 PPGVWPANPAPITQTVIHTVQSAPGQMFSTPAIPPMYPHPAYPMPFITTILGGLYPSKS
 HS ILLSGTVLPSAQRFHINLCSGNHIAFHLNPRFDENAVVRNTQIDNSWGSEERSLPRKMPF

 G9 ILLSGTVLPSAQRFHINLCSGNHIAFHLNPRFDENAVVRNTQIDNSWGSEERSLPRKMPF
 5 HS VRGQSFSVWILCEAHCLKVAVDGQHLFEYYHRLRLPTINRLEVGGDIQLTHVQT

 G9 VRGQSFSVWILCGAHCLKVAVDGQHLFEYYHRLRLPTINRLEVGGDIQLTHVQT

Table 3

10 HS MAFSGSQAPYLSPAVPFSGTIQGGLQDGLQITVNGTVLSSSGTRFAVNFQTGFSGNDIAF
 . .*..*. *.**.*.*****.***.*. *. .*. .*.**.*. .*.*****
 MM MALFSAQSPYINPIIPFTGPIQGGLEGLQVTLQGT-KSFAQRFVVFQNSFNGNDIAF
 HS HFNPRFEDGGYVVCNTRQNGSWGPEERKTHMPFQKGMPPDLCLVQSSDFKVMVNGILFV
 15 *****.*****.*** *****.*****.*****.*.*****. **.
 MM HFNPRFEEGGYVVCNTRQNGSWGPEERKTHMPFQKGMPPDLCLVQSEFKVMVNGKFFV
 HS QYFHRVPFHRVDTISVNGSVQLSYISFQNPRTVPVQPAFSTVPFSQPVCFPPRPRGRRQK
 ** ****.* ****.*.***.***. .*.***.***. .***** **. *.**.*.
 MM QYQHRVPYHLVDTIAVSGCLKLSFITFQNS-AAPVQHVFSTLQFSQPVPFPRTPKGRKQK
 20 HS PPGVWPANPAPITQTVIHTVQSAPGQMFSTPAIPPMYPHPAYPMPFITTILGGLYPSKS
**.*.***.***.***.***.***.***.***.***.***.***.***.***.***.***
 MM TQNFRPAHQAPMAQTTIHMVHSTPGQMFSTPGIPPVYPTPAYTIPFYTPIPNGLYPSKS
 HS ILLSGTVLPSAQRFHINLCSGNHIAFHLNPRFDENAVVRNTQIDNSWGSEERSLPRKMPF
 *.**.*.***.* *****.***.*****.*****.*****.*****.***
 25 MM IMISGNVLPDATRFHINLRCGGDIAFHLNPRFNENAVVRNTQINNSWGQEERSLLGRMPF
 HS VRGQSFSVWILCEAHCLKVAVDGQHLFEYYHRLRLPTINRLEVGGDIQLTHVQT
 *****.***.***.***.***.*****.***.***.***.*****
 MM SRGQSFSVWIICEGHCFKVAVNGQHMCEYYHRLKLNLDINTLEVAGDIQLTHVQT

30

(2) Protein Synthesis by In Vitro Translation

Vector pHP01461 bearing the cDNA of the present invention was used for in vitro translation with a T_NT rabbit reticulocyte lysate kit (Promega). In this case, [³⁵S]methionine was added to
 35 label the expression product with a radioisotope. Each of the

reactions was carried out according to the protocols attached to the kit. Two micrograms of plasmid pHP01416 was reacted at 30°C for 90 minutes in a total 100 µl volume of the reaction solution containing 50 µl of T_NT rabbit reticulocyte lysate, 4 µl of a buffer solution (attached to kit), 2 µl of an amino acid mixture (methionine-free), 8 µl of [³⁵S]methionine (Amersham) (0.37 MBq/µl), 2 µl of T7RNA polymerase, and 80 U of RNasin. To 3 µl of the resulting reaction solution was added 2 µl of the SDS sampling buffer (125 mM Tris-hydrochloric acid buffer, pH 6.8, 120 mM 2-mercaptoethanol, 2% SDS solution, 0.025% bromophenol blue, and 20% glycerol) and the resulting mixture was heated at 95°C for 3 minutes and then subjected to SDS-polyacrylamide gel electrophoresis. Determination of the molecular weight of the translation product by carrying out the autoradiograph indicated that the cDNA of the present invention yielded the translation product with the molecular mass of about 40 kDa (Figure 2). This value is consistent with the molecular weight of 39,517 predicted for the putative protein from the base sequence represented by Sequence No. 2, thereby indicating that this cDNA certainly codes for the protein represented by Sequence No. 2.

(3) Measurement of Lactose-Binding Activity of In-Vitro Translation Product

After 100 ml of a Sepharose-4B gel suspension (Pharmacia) was washed well with 0.5 M sodium carbonate, the gel was suspended in 100 ml of 0.5 M sodium carbonate. Thereto was added 10 ml of vinyl sulfone and the resulting mixture was gently stirred at room temperature for one hour. After washing with 0.5 M sodium carbonate,

the gel was suspended in a solution of 10% lactose and 0.5 M sodium carbonate, and the resulting suspension was stirred gently overnight at room temperature. The resulting gel was washed in order with 0.5 M sodium carbonate, water, and 0.05 M phosphate buffer (pH 7.0). The thus-obtained lactosyl-Sepharose-4B gel was stored at 4°C in the 0.05 M phosphate buffer (pH 7.0) containing 0.02% sodium azide.

By chromatography of 100 µl of the in-vitro translation solution on the previously-prepared lactosyl-Sepharose-4B column (a bed volume of 4.5 ml), the column was washed with 20 ml of a column buffer solution for lactose column (20 mM Tris-hydrochloric acid buffer, pH 7.5, 2 mM EDTA, 150 mM NaCl, 4 mM 2-mercaptoethanol, and 0.01% Triton X-100) and then eluted with 20 ml of the column buffer solution containing 0.3 M lactose. As the result, it is indicated that the protein of the present invention possesses the lactose-binding activity from the observation that the 40-kDa translation product was contained in the eluates (Figure 2).

(4) Expression of Galectin-9-like Protein by *Escherichia coli* and Lactose-Binding Activity

After digestion of 1 µg of plasmid pHP01461 with 20 units of EcoRI and 20 units of NotI, followed by electrophoresis on 0.8% agarose gel, an about 1.7-kbp DNA fragment was cut off from the gel. Then, after digestion of 1 µg of pET21a (Novagen), an expression vector for *Escherichia coli*, with 20 units of EcoRI and 20 units of NotI, followed by electrophoresis on 0.8% agarose gel, an about 5.3-kbp DNA fragment was cut off from the gel. Both

DNA fragments were ligated by using a ligation kit and then *Escherichia coli* JM109 was transformed. Plasmid pET-1461 was prepared from the transformant and the objective recombinant was identified by the restriction enzyme cleavage map.

5 Two strands of an oligonucleotide primer PR1 (5'-CGCATATGGCCTTCAGCGGTTCCCAGGC-3') and PR2 (5'-AACGGCACCGTGGAGAAGGCAGGCTGAACA-3') were synthesized by using a DNA synthesizer (Applied Biosystems) according to the attached protocol. The 5'-translation region in the cDNA was amplified with
10 the PCR kit (TAKARA SHUZO) using 1 ng of plasmid pHP01461 as well as 100 pmole each of primers PR1 and PR2. After phenol extraction and ethanol extraction, followed by digestion with 20 units of SacI and NdeI, the reaction product was subjected to 1.2% agarose electrophoresis to cut off an about 320-bp DNA fragment for
15 purification.

After digestion of 1 µg of plasmid pET-1461 with 20 units of SacI and NdeI, followed by electrophoresis on 0.8% agarose gel, a 3.8-kbp DNA fragment was cut off from the gel. This DNA fragment and the about 320-bp DNA fragment prepared previously by PCR were
20 ligated by using a ligation kit and then *Escherichia coli* BL21 (DE3) was transformed. Plasmid pET-1461 was prepared from the transformant and the objective recombinant was identified by the restriction enzyme cleavage map.

A suspension of 2 ml of an overnight-incubated liquid of
25 pET1461/BL21 (DE3) in 100 ml of the LB culture medium containing 100 µg/ml of ampicillin was incubated in a shaker at 37°C and isopropylthiogalactoside was added so as to make 1 mM when A₆₀₀

reached about 0.5. After further incubation at 37°C for 3 hours, the mycelia collected by centrifugation were suspended in 25 ml of the column buffer for lactose column. After sonication, the suspension was centrifuged and the supernatant was charged into the previously-prepared, lactosyl-Sepharose-4B column (a 2-ml bed volume). The column was washed with 10 ml of the column buffer for lactose column and then eluted with 5 ml of the column buffer containing 0.3 M lactose. The SDS-polyacrylamide electrophoresis of the eluted protein indicated the presence of a single band at the position of 40 kDa. This molecular mass value is consistent with the molecular weight predicted for the human galectin-9-like protein. That is to say, the human galectin-9-like protein expressed by *Escherichia coli* was indicated to possess the lactose-binding activity.

(5) Northern Blot Hybridization

Northern blot hybridization was carried out in order to examine the expression pattern in the human tissues. Filters where poly(A)⁺ RNAs isolated from each of human tissues are blotted were purchased from Clontech. After digestion of plasmid pHP01049 with ApaLI and BstXI, followed by agarose-gel electrophoresis to isolate a cDNA fragment, labeling with [³²P]dCTP (Amersham) was carried out by using a random primer labeling kit (TAKARA SHUZO). Furthermore, the inserted portion was subjected to the terminal ³²P-labeling with a synthetic oligonucleotide 5'-AACGGCACCGTGGAGAAGGCAGGCTGAGCA-3' using T4 polynucleotide kinase. The hybridization was carried out by using a solution attached to the blot paper according to the protocol.

In the case in which the cDNA fragment was employed as a probe, the strongest expression was observed in the peripheral blood and, besides, expression was observed in the heart, the placenta, the lung, the spleen, the thymus, the ovary, the small intestine, and the large intestine. In each case, the size of the transcription product was about 2 kb (Figure 3). On the other hand, in the case in which the inserted portion was used as a probe, a different result was obtained (Figure 4). The about 2kb band was the most intense in the small intestine and the large intestine with weak expression being observed in the lung and the peripheral blood. Beside the band of this size, a strong band of less than 1 kb was observed in the liver and also a band of about 2.4 kb was observed in the kidney. In this way, the expression pattern of human galectin-9 is different in the case in which the inserted portion was used as a probe, so that the proteins of the present invention are indicated to undergo an expression control different from that of known galectin-9 and, also, are predicted to be different in their function.

The present invention provides human cDNAs coding for galectin-9-like proteins and proteins encoded by these human cDNAs. Said recombinant proteins can be expressed in large amounts by utilizing the cDNAs of the present invention. Said recombinant proteins can be employed as pharmaceuticals/research reagents.

In addition to the activities and uses described above, the polynucleotides and proteins of the present invention may exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses

or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for
5 introduction of DNA).

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for
10 analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers
15 or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic
20 fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization
25 techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such

as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein
5 with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput
10 screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either
15 constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to
20 identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being
25 developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known

to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in
5 Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses
10 include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid
15 or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

20 A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known
25 cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of

a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165,
5 HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in
10 Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986;
15 Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of
20 spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human
25 Interferon γ , Schreiber, R.D. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E.

5 In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human
10 interleukin 6-Nordan, R. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In Current
15 Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

20 Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology,
25 Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte

Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein.

10 A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations.

15 These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention,

20 including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the

25 treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue

disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-

5 host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired

10 (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already

15 in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires

20 continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be

25 demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions

(including without limitation B lymphocyte antigen functions (such as , for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in

5 graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the

10 transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B

15 lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by

20 immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of

25 these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte

antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive

T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases.

5 Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

10 Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the commoncold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

20 Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into

the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or
5 a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.

In another application, up regulation or enhancement of
10 antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfect with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome
15 tumor-specific tolerance in the subject. If desired, the tumor cell can be transfect to express a combination of peptides. For example, tumor cells obtained from a patient can be transfect ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with
20 a peptide having B7-1-like activity and/or B7-3-like activity. The transfect tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfect cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.

25 The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells

to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected
5 with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression
10 of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II
15 associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human
20 subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity
25 include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing

Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro

assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

- 5 Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al.,
10 Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical
15 Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

- Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte
20 homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry
25 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell

commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 5 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal 10 biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating 15 various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, 20 for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place 25 of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned

hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in
5 repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

10 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will
15 identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

20 Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 265-268,
25 Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K.

and Briddell, R.A. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In Culture
5 of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994;
10 Long term culture initiating cell assay, Sutherland, H.J. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Tissue Growth Activity

A protein of the present invention also may have utility
15 in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage
20 and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and
25 also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced

craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or

ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular

diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote
5 better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other
10 tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of
15 fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions
20 resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

25 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without

limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

5 Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

10 Activin/Inhibin Activity

 A protein of the present invention may also exhibit activin-
or inhibin-related activities. Inhibins are characterized by
their ability to inhibit the release of follicle stimulating
hormone (FSH), while activins and are characterized by their
15 ability to stimulate the release of follicle stimulating hormone
(FSH). Thus, a protein of the present invention, alone or in
heterodimers with a member of the inhibin α family, may be useful
as a contraceptive based on the ability of inhibins to decrease
fertility in female mammals and decrease spermatogenesis in male
20 mammals. Administration of sufficient amounts of other inhibins
can induce infertility in these mammals. Alternatively, the
protein of the invention, as a homodimer or as a heterodimer with
other protein subunits of the inhibin- β group, may be useful as
a fertility inducing therapeutic, based upon the ability of
25 activin molecules in stimulating FSH release from cells of the
anterior pituitary. See, for example, United States Patent
4,798,885. A protein of the invention may also be useful for

advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other
5 means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663,
10 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts,
15 neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to
20 tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a
25 particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability

to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

- 5 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, 15 W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 20 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected 25 to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds

resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction
5 of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin.
10 Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

Receptor/Ligand Activity

A protein of the present invention may also demonstrate
15 activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell
20 interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful
25 for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of

receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

5 Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular
10 Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

15 Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell
20 interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins
25 exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such

as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel
5 disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Tumor Inhibition Activity

10 In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity
15 by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or
20 cell types which promote tumor growth

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents,
25 including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily

characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

CLAIMS

1. A protein containing the amino acid sequence represented by Sequence No. 1.

2. The protein described in Claim 1 containing the amino
5 acid sequence represented by Sequence No. 2.

3. A cDNA containing the base sequence represented by Sequence No. 3.

4. The cDNA described in Claim 3 containing the base sequence represented by Sequence No. 4.

10 5. The cDNA described in Claim 3 or Claim 4 which comprises
the base sequence represented by Sequence No. 5.

1/4




Figure 1

2/4




Figure 2




Figure 3




Figure 4

1, Heart; 2, Brain; 3, Placenta; 4, Lung; 5, Liver;
 6, Skeletal muscle; 7, Kidney; 8, Pancreas;
 9, Spleen; 10, Thymus; 11, Prostate Gland;
 12, Testis; 13, Ovary; 14, Small Intestine;
 15, Large Intestine; 16, Peripheral Blood Leukocyte

"Express Mail" mailing label number: EE632046274US
Date of Deposit: February 17, 2000
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner For Patents, Washington, D.C. 20231

GI 6707PCT-US

DECLARATION and POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HUMAN GALECTIN-9-LIKE PROTEINS AND CDNAS ENCODING THESE PROTEINS

-the specification of which is attached hereto. If not attached hereto, the specification was filed on _____ as United States Application No. _____ and was amended on _____.

X was filed on 19 August 1998 as PCT International Application No. PCT/JP98/03670 and was amended Under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information of which I am aware which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Foreign Application(s)

<u>Number</u>	<u>Country</u>	<u>Filing Date</u>	<u>Priority Claimed</u>
<u>9-226468</u>	<u>Japan</u>	<u>22 August 1997</u>	<u>Yes</u>

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.

Filing Date

Status

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

5 Thomas J. DesRosier, Reg. No. 30,168

Ellen J. Kapinos, Reg. No. 32,245

Steven R. Lazar, Reg. No. 32,618

Scott A. Brown, Reg. No. 32,724

Suzanne A. Sprunger, Ph. D., Reg. No. 41,323

Address all telephone calls to Suzanne A. Sprunger, Ph.D. at Telephone No. (617) 498-8284. **Address all correspondence to LEGAL AFFAIRS, GENETICS INSTITUTE, INC., 87 CambridgePark Drive, Cambridge, Massachusetts 02140.**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Seishi KATO

Inventor's signature Seishi Kato Date December 9, 1999

Residence Sagamihara-shi, KANAGAWA, JAPAN JPX

Citizenship JAPAN

Post Office Address 3-46-50, Wakamatsu, Sagamihara-shi, Kanagawa 229-0014 JAPAN

2W Full name of second joint inventor Tomoko KIMURA

Inventor's signature Tomoko Kimura Date December 9, 1999

Residence Kawasaki-shi, KANAGAWA, JAPAN JPX

Citizenship JAPAN

Post Office Address 302, 4-1-28, Nishiikuta, Tama-ku, Kawasaki-shi, Kanagawa 214-0037 JAPAN

30 Full name of third joint inventor Shingo SEKINE

Inventor's signature Shingo Sekine Date December 9, 1999

Residence Ageo-shi, SAITAMA, JAPAN JPX

Citizenship JAPAN

Post Office Address Remonzu 101, 2-8-15, Atago, Ageo-shi, Saitama 362-0034 JAPAN

40 Full name of fourth joint inventor Kouju KAMATA

Inventor's signature Kouju Kamata Date December 9, 1999

Residence Sagamihara-shi, KANAGAWA, JAPAN JPX

Citizenship JAPAN

Post Office Address 5-17-8, Kamitsuruma, Sagamihara-shi, Kanagawa 228-0802 JAPAN

Sequence Listing

<110> Sagami Chemical Research Center

5 <120> Human galactin-9-Like Proteins and cDNAs Encoding these Proteins

<130> 660851

<140>

10 <141>

<150> Japan 9-226468

<151> 1997-08-22

"Express Mail" mailing label number EE63204627401Date of Deposit February 17, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner For Patents, Washington, D.C. 20231

15 <160> 5

<170> Windows 95 (Word 98)

<210> 1

20 <211> 32

<212> PRT

<213> Homo sapiens

<400> 1

25 Asn Pro Arg Thr Val Pro Val Gln Pro Ala Phe Ser Thr Val Pro Phe

1

5

10

15

Ser Gln Pro Val Cys Phe Pro Pro Arg Pro Arg Gly Arg Arg Gln Lys

20

25

30

30 <210> 2

<211> 355

<212> PRT

<213> Homo sapiens

35 <400> 2

Met Ala Phe Ser Gly Ser Gln Ala Pro Tyr Leu Ser Pro Ala Val Pro

1

5

10

15

Phe Ser Gly Thr Ile Gln Gly Gly Leu Gln Asp Gly Leu Gln Ile Thr

20 25 30
 Val Asn Gly Thr Val Leu Ser Ser Ser Gly Thr Arg Phe Ala Val Asn
 35 40 45
 Phe Gln Thr Gly Phe Ser Gly Asn Asp Ile Ala Phe His Phe Asn Pro
 5 50 55 60
 Arg Phe Glu Asp Gly Gly Tyr Val Val Cys Asn Thr Arg Gln Asn Gly
 65 70 75 80
 Ser Trp Gly Pro Glu Glu Arg Lys Thr His Met Pro Phe Gln Lys Gly
 85 90 95
 10 Met Pro Phe Asp Leu Cys Phe Leu Val Gln Ser Ser Asp Phe Lys Val
 100 105 110
 Met Val Asn Gly Ile Leu Phe Val Gln Tyr Phe His Arg Val Pro Phe
 115 120 125
 His Arg Val Asp Thr Ile Ser Val Asn Gly Ser Val Gln Leu Ser Tyr
 15 130 135 140
 Ile Ser Phe Gln Asn Pro Arg Thr Val Pro Val Gln Pro Ala Phe Ser
 145 150 155 160
 Thr Val Pro Phe Ser Gln Pro Val Cys Phe Pro Pro Arg Pro Arg Gly
 165 170 175
 20 Arg Arg Gln Lys Pro Pro Gly Val Trp Pro Ala Asn Pro Ala Pro Ile
 180 185 190
 Thr Gln Thr Val Ile His Thr Val Gln Ser Ala Pro Gly Gln Met Phe
 195 200 205
 Ser Thr Pro Ala Ile Pro Pro Met Met Tyr Pro His Pro Ala Tyr Pro
 25 210 215 220
 Met Pro Phe Ile Thr Thr Ile Leu Gly Gly Leu Tyr Pro Ser Lys Ser
 225 230 235 240
 Ile Leu Leu Ser Gly Thr Val Leu Pro Ser Ala Gln Arg Phe His Ile
 245 250 255
 30 Asn Leu Cys Ser Gly Asn His Ile Ala Phe His Leu Asn Pro Arg Phe
 260 265 270
 Asp Glu Asn Ala Val Val Arg Asn Thr Gln Ile Asp Asn Ser Trp Gly
 275 280 285
 Ser Glu Glu Arg Ser Leu Pro Arg Lys Met Pro Phe Val Arg Gly Gln
 35 290 295 300
 Ser Phe Ser Val Trp Ile Leu Cys Glu Ala His Cys Leu Lys Val Ala
 305 310 315 320
 Val Asp Gly Gln His Leu Phe Glu Tyr Tyr His Arg Leu Arg Asn Leu

325 330 335
 Pro Thr Ile Asn Arg Leu Glu Val Gly Gly Asp Ile Gln Leu Thr His
 340 345 350

Val Gln Thr

5 355

<210> 3

<211> 96

<212> DNA

10 <213> Homo sapiens

<400> 3

aacccccgca cagtcctgt tcagcctgcc ttctccacgg tgccgttctc ccagcctgtc 60

tgtttccac ccaggcccag ggggcgcaga caaaaa 96

15

<210> 4

<211> 1065

<212> DNA

<213> Homo sapiens

20

<400> 4

atggccttca gcggttccca ggctccctac ctgagtccag ctgtccctt ttctgggact 60

attcaaggag gtctccagga cggacttcag atcactgtca atgggaccgt tctcagctcc 120

agtggaaacca ggtttgtgt gaactttcag actggcttca gtggaaatga cattgccttc 180

25 cacttcaacc ctcggtttga agatggaggg tacgtggtgt gcaacacgag gcagaacgga 240

agctgggggc ccgaggagag gaagacacac atgcctttcc agaaggggat gccctttgac 300

ctctgcttcc tgggtgcagag ctccagattc aaggtgatgg tgaacgggat cctcttcgtg 360

cagtacttcc accgcgtgcc ctccaccgt gtggacacca tctccgtcaa tggctctgtg 420

cagctgtcct acatcagctt ccagaacccc cgcacagtcc ctgttcagcc tgccttctcc 480

30 acggtgccgt tctcccagcc tgtctgtttc ccaccaggc ccagggggcg cagacaaaaa 540

cctcccggcg tgtggcctgc caaccggct ccattacc cagacagtcac ccacacagtg 600

cagagcgccc ctggacagat gttctctact cccgccatcc cactatgat gtacccccac 660

cccgcctatc cgtatgcctt catcaccacc attctgggag ggctgtaccc atccaagtcc 720

atctctctgt caggcactgt cctgccaggt gctcagaggt tccacatcaa cctgtgtctt 780

35 gggaaccaca tcgccttcca cctgaacccc cgttttgatg agaattgtgt ggtccgcaac 840

accagatcg acaactcctg ggggtctgag gagcgaagtc tgccccgaaa aatgcccttc 900

gtccgtggcc agagcttctc agtgtggatc ttgtgtgaag ctactgcct caaggtggcc 960

gtggatggtc agcacctgtt tgaatactac catcgctga ggaacctgcc caccatcaac 1020

004730-730300

agactggaag tggggggcga catccagctg acccatgtgc agaca

1065

<210> 5

<211> 1725

5 <212> DNA

<213> Homo sapiens

<400> 5

10	tttctttgtt aagtcgttcc ctctacaaag gacttcctag tgggtgtgaa aggcagcggg	60
	ggccacagag gcggcggaga g atg gcc ttc agc ggt tcc cag gct ccc tac	111
	Met Ala Phe Ser Gly Ser Gln Ala Pro Tyr	
	1 5 10	
	ctg agt cca gct gtc ccc ttt tct ggg act att caa gga ggt ctc cag	159
	Leu Ser Pro Ala Val Pro Phe Ser Gly Thr Ile Gln Gly Gly Leu Gln	
15	15 20 25	
	gac gga ctt cag atc act gtc aat ggg acc gtt ctc agc tcc agt gga	207
	Asp Gly Leu Gln Ile Thr Val Asn Gly Thr Val Leu Ser Ser Ser Gly	
	30 35 40	
	acc agg ttt gct gtg aac ttt cag act ggc ttc agt gga aat gac att	255
20	Thr Arg Phe Ala Val Asn Phe Gln Thr Gly Phe Ser Gly Asn Asp Ile	
	45 50 55	
	gcc ttc cac ttc aac cct cgg ttt gaa gat gga ggg tac gtg gtg tgc	303
	Ala Phe His Phe Asn Pro Arg Phe Glu Asp Gly Gly Tyr Val Val Cys	
	60 65 70	
25	aac acg agg cag aac gga agc tgg ggg ccc gag gag agg aag aca cac	351
	Asn Thr Arg Gln Asn Gly Ser Trp Gly Pro Glu Glu Arg Lys Thr His	
	75 80 85 90	
	atg cct ttc cag aag ggg atg ccc ttt gac ctc tgc ttc ctg gtg cag	399
	Met Pro Phe Gln Lys Gly Met Pro Phe Asp Leu Cys Phe Leu Val Gln	
30	95 100 105	
	agc tca gat ttc aag gtg atg gtg aac ggg atc ctc ttc gtg cag tac	447
	Ser Ser Asp Phe Lys Val Met Val Asn Gly Ile Leu Phe Val Gln Tyr	
	110 115 120	
	ttc cac cgc gtg ccc ttc cac cgt gtg gac acc atc tcc gtc aat ggc	495
35	Phe His Arg Val Pro Phe His Arg Val Asp Thr Ile Ser Val Asn Gly	
	125 130 135	
	tct gtg cag ctg tcc tac atc agc ttc cag aac ccc cgc aca gtc cct	543
	Ser Val Gln Leu Ser Tyr Ile Ser Phe Gln Asn Pro Arg Thr Val Pro	

G:\9805\980504\980504-001\980504-001-001

	140	145	150	
	gtt cag cct gcc ttc tcc acg gtg ccg ttc tcc cag cct gtc tgt ttc			591
	Val Gln Pro Ala Phe Ser Thr Val Pro Phe Ser Gln Pro Val Cys Phe			
	155	160	165	170
5	cca ccc agg ccc agg ggg cgc aga caa aaa cct ccc ggc gtg tgg cct			639
	Pro Pro Arg Pro Arg Gly Arg Arg Gln Lys Pro Pro Gly Val Trp Pro			
	175	180	185	
	gcc aac ccg gct ccc att acc cag aca gtc atc cac aca gtg cag agc			687
	Ala Asn Pro Ala Pro Ile Thr Gln Thr Val Ile His Thr Val Gln Ser			
10	190	195	200	
	gcc cct gga cag atg ttc tct act ccc gcc atc cca cct atg atg tac			735
	Ala Pro Gly Gln Met Phe Ser Thr Pro Ala Ile Pro Pro Met Met Tyr			
	205	210	215	
	ccc cac ccc gcc tat ccg atg cct ttc atc acc acc att ctg gga ggg			783
15	Pro His Pro Ala Tyr Pro Met Pro Phe Ile Thr Thr Ile Leu Gly Gly			
	220	225	230	
	ctg tac cca tcc aag tcc atc ctc ctg tca ggc act gtc ctg ccc agt			831
	Leu Tyr Pro Ser Lys Ser Ile Leu Leu Ser Gly Thr Val Leu Pro Ser			
	235	240	245	250
20	gct cag agg ttc cac atc aac ctg tgc tct ggg aac cac atc gcc ttc			879
	Ala Gln Arg Phe His Ile Asn Leu Cys Ser Gly Asn His Ile Ala Phe			
	255	260	265	
	cac ctg aac ccc cgt ttt gat gag aat gct gtg gtc cgc aac acc cag			927
	His Leu Asn Pro Arg Phe Asp Glu Asn Ala Val Val Arg Asn Thr Gln			
25	270	275	280	
	atc gac aac tcc tgg ggg tct gag gag cga agt ctg ccc cga aaa atg			975
	Ile Asp Asn Ser Trp Gly Ser Glu Glu Arg Ser Leu Pro Arg Lys Met			
	285	290	295	
	ccc ttc gtc cgt ggc cag agc ttc tca gtg tgg atc ttg tgt gaa gct			1023
30	Pro Phe Val Arg Gly Gln Ser Phe Ser Val Trp Ile Leu Cys Glu Ala			
	300	305	310	
	cac tgc ctc aag gtg gcc gtg gat ggt cag cac ctg ttt gaa tac tac			1071
	His Cys Leu Lys Val Ala Val Asp Gly Gln His Leu Phe Glu Tyr Tyr			
	315	320	325	330
35	cat cgc ctg agg aac ctg ccc acc atc aac aga ctg gaa gtg ggg ggc			1119
	His Arg Leu Arg Asn Leu Pro Thr Ile Asn Arg Leu Glu Val Gly Gly			
	335	340	345	
	gac atc cag ctg acc cat gtg cag aca taggcggcctt cctggccctg gggc			1170

Asp Ile Gln Leu Thr His Val Gln Thr

350

355

5 cgggggctgg ggtgtggggc agtctgggtc ctctcatcat cccacttcc caggcccagc 1230
 ctttccaacc ctgcctggga tctgggcttt aatgcagagg ccatgtcctt gtctggtcct 1290
 gcttctggct acagccaccc tggaacggag aaggcagctg acggggattg ccttcctcag 1350
 ccgcagcagc acctggggct ccagctgctg gaatcctacc atcccaggag gcaggcacag 1410
 ccaggagagag gggaggagtg ggcagtgaag atgaagcccc atgctcagtc ccctcccatc 1470
 cccacgcag ctccacccca gtcccaagcc accagctgtc tgctcctggt gggagggtggc 1530
 ctctcagcc cctcctctct gacctttaac ctactctca ccttgaccg tgcaccaacc 1590
 10 cttcacccct cctggaaagc aggctgatg gcttccact ggctccacc acctgaccag 1650
 agtgtttctt tcagaggact ggctcctttc ccagtgtcct taaaataaag aaatgaaaat 1710
 gcttgttggc acatt 1725

<210> 6

15 <211> 355

<212> PRT

<213> Homo sapiens

<400> 6

20

Met Ala Phe Ser Gly Ser Gln Ala Pro Tyr

1

5

10

Leu Ser Pro Ala Val Pro Phe Ser Gly Thr Ile Gln Gly Gly Leu Gln

15

20

25

Asp Gly Leu Gln Ile Thr Val Asn Gly Thr Val Leu Ser Ser Ser Gly

25

30

35

40

Thr Arg Phe Ala Val Asn Phe Gln Thr Gly Phe Ser Gly Asn Asp Ile

45

50

55

Ala Phe His Phe Asn Pro Arg Phe Glu Asp Gly Gly Tyr Val Val Cys

60

65

70

30

Asn Thr Arg Gln Asn Gly Ser Trp Gly Pro Glu Glu Arg Lys Thr His

75

80

85

90

Met Pro Phe Gln Lys Gly Met Pro Phe Asp Leu Cys Phe Leu Val Gln

95

100

105

Ser Ser Asp Phe Lys Val Met Val Asn Gly Ile Leu Phe Val Gln Tyr

35

110

115

120

Phe His Arg Val Pro Phe His Arg Val Asp Thr Ile Ser Val Asn Gly

125

130

135

Ser Val Gln Leu Ser Tyr Ile Ser Phe Gln Asn Pro Arg Thr Val Pro

140 145 150
Val Gln Pro Ala Phe Ser Thr Val Pro Phe Ser Gln Pro Val Cys Phe
155 160 165 170
Pro Pro Arg Pro Arg Gly Arg Arg Gln Lys Pro Pro Gly Val Trp Pro
5 175 180 185
Ala Asn Pro Ala Pro Ile Thr Gln Thr Val Ile His Thr Val Gln Ser
190 195 200
Ala Pro Gly Gln Met Phe Ser Thr Pro Ala Ile Pro Pro Met Met Tyr
205 210 215
10 Pro His Pro Ala Tyr Pro Met Pro Phe Ile Thr Thr Ile Leu Gly Gly
220 225 230
Leu Tyr Pro Ser Lys Ser Ile Leu Leu Ser Gly Thr Val Leu Pro Ser
235 240 245 250
Ala Gln Arg Phe His Ile Asn Leu Cys Ser Gly Asn His Ile Ala Phe
15 255 260 265
His Leu Asn Pro Arg Phe Asp Glu Asn Ala Val Val Arg Asn Thr Gln
270 275 280
Ile Asp Asn Ser Trp Gly Ser Glu Glu Arg Ser Leu Pro Arg Lys Met
285 290 295
20 Pro Phe Val Arg Gly Gln Ser Phe Ser Val Trp Ile Leu Cys Glu Ala
300 305 310
His Cys Leu Lys Val Ala Val Asp Gly Gln His Leu Phe Glu Tyr Tyr
315 320 325 330
His Arg Leu Arg Asn Leu Pro Thr Ile Asn Arg Leu Glu Val Gly Gly
25 335 340 345
Asp Ile Gln Leu Thr His Val Gln Thr
350 355